Initial public offerings scheduled to debut next week

NEW YORK, N.Y. – The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT ( and SEC filings.

Week of October 13:

Atara Biotherapeutics Inc. – Brisbane, Calif., 5 million shares, priced $14 to $16, managed by Goldman Sachs and Citigroup. Proposed Nasdaq symbol ATRA. Business: Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

Dominion Midstream Partners LP – Richmond, Va., 17.5 million shares, priced $19 to $21, managed by Barclays, Citigroup, and J.P. Morgan. Proposed NYSE symbol DM. Business: Operates Dominion Resources’ liquefied natural gas import, storage, regasification and transportation assets.

EndoStim Inc. – St. Louis, 3.2 million shares, priced, $10 to $12, managed by Wedbush PacGrow. Proposed Nasdaq Capital Market symbol STIM. Business: Medical device company developing a neurostimulation system for treatment of gastroesophageal reflux disease, or GERD.

Forward Pharma A/S – Copenhagen, Denmark, 9.5 million American depositary shares, each representing one ordinary share, priced $20 to $22, managed by Leerink, Jefferies, and RBC. Proposed Nasdaq symbol FWP. Business: Biotech developing a slow release formulation of a multiple sclerosis treatment.

Great Western Bancorp – Sioux Falls, S.D., 16 million shares, priced $21 to $24, managed by Deutsche Bank, and BofA Merrill Lynch. Proposed NYSE symbol GWB. Business: Agribusiness-focused Midwestern bank with 162 branches.

Hydra Industries Acquisition Corp. – New York, 10 million units, each consisting of one common share and one warrant, priced at $10 each, managed by UBS. Proposed Nasdaq symbol HDRAU. Business: Blank check company formed by A. Lorne Weil and sponsored by Macquarie.

Virobay Inc. – Menlo Park, Calif., 3.8 million shares, priced $12 to $14, managed by Piper Jaffray, and JMP. Proposed Nasdaq symbol VBAY. Business: An early-stage biotech developing a drug platform for pain, and autoimmune diseases.

Xenon Pharmaceuticals Inc. – Burnaby, B.C., Canada, 4 million shares, priced $10 to $12, managed by Jefferies, and Wells Fargo. Proposed Nasdaq symbol XENE. Business: An early-stage biotech with a gene therapy discovery platform for rare diseases.

Zayo Group Holdings Inc. – Boulder, Colo., 28.9 million shares, priced $21 to $24, managed by Morgan Stanley, Barclays, and Goldman Sachs. Proposed NYSE symbol ZAYO. Business: A national provider of fiber optic bandwidth infrastructure and colocation services.